Feb 24, 2025 | Benefits preservation, Case Study, Cost Savings, Drug costs, MedBen Rx, Rx Costs, Savings, Specialty Drugs
High-cost specialty drugs can make up more than 60% of a health plan’s pharmacy costs. MedBen Rx’s benefit preservation program is designed to make certain that members have continued access to medications while reducing specialty drug spend to the greatest...
Feb 10, 2025 | Cost Savings, Drug costs, Pharmacogenomics, Rx Costs, Savings
Now available through MedBen Rx, pharmacogenomic testing is transforming health care through safer and more effective personalized medicine. Determining how genes affect a person’s response to drugs not only improves patient outcomes, but it also helps control...
Jan 10, 2025 | Drug costs, Drug makers, News
Pharmaceutical companies are planning to increase prices on over 250 brand-name medications in the United States at the beginning of 2025, according to an analysis by health care research firm 3 Axis Advisors. That’s a notable drop from last January, during...
Oct 29, 2024 | Client Report, Cost projections, Cost Savings, Drug costs, MedBen Rx, Prescription drugs, Rx Costs, Transparency, Trend
Health care costs in the United States are projected to see their steepest rise in over a decade during 2025, with multiple industry analyses forecasting increases between 7% and 8% year-over-year (see table below). However, MedBen offers solutions that directly...
Oct 15, 2024 | Benefits preservation, Biosimilar, Claims, Cost Savings, Drug costs, Rx Costs, Savings, Specialty Drugs
Specialty drugs continue to drive up pharmacy costs, accounting for over 50% of total drug spend for many self-funded health plans, despite being used by a small percentage of patients. But pharmaceutical and administrative solutions are available to help reduce that...
Sep 3, 2024 | Biosimilar, Drug costs, GLP-1s, Humira, Mounjaro, Ozempic, Rx Costs, Stelara, Trulicity, Wegovy
Humira continued to be the costliest prescription drug for self-funded health plans in 2023 by a comfortable margin, according to a recent Milliman commercial drug trends review. Used to treat a variety of conditions from Crohn’s to rheumatoid arthritis and psoriatic...
